A practical reference on fatty acid oxidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
=== Medical Student Training in Aging Research (MSTAR) === The University of Texas Medical Student Training in Aging Research (UT-MSTAR) is an NIH-funded T35 short-term research training program administered by the Barshop Institute and supported by the National Institute on Aging. Established in 2025, the program is directed by Elena Volpi, MD, PhD, FGSA, and represents a unique statewide collaboration among the four largest medical schools in The University of Texas System: UT Health San Antonio, UTHealth Houston, UT Medical Branch, and UT Southwestern Medical Center. The program was created to address the growing national need for physician-scientists with expertise in aging research and geriatric medicine by introducing medical students to aging research early in their professional training. UT-MSTAR provides approximately 20 first-year medical students each year with an intensive eight-week summer research experience under the mentorship of accomplished investigators conducting basic, translational, clinical, behavioral, and population-based aging research. Students are paired with faculty mentors whose research encompasses the biology of aging, geroscience, Alzheimer's disease and related dementias, cardiovascular disease, metabolic disorders, frailty, sarcopenia, health disparities, and other age-related conditions.
== External links == Shodex Worldwide and Asia general website Shodex North and Latin America website Shodex Europe, Middle East, Africa website Showa Denko Develops New Shodex™ Analytical Column Resonac Website about Shodex HPLC columns
==== General consensus on use ==== There is consensus amongst stroke specialists that tPA is the standard of care for eligible stroke patients, and benefits outweigh the risks. There is significant debate mainly in the emergency medicine community regarding recombinant tPA's effectiveness in ischemic stroke. The NNT Group on evidence-based medicine concluded that it was inappropriate to combine these twelve trials into a single analysis, because of substantial clinical heterogeneity (i.e., variations in study design, setting, and population characteristics). Examining each study individually, the NNT group noted that two of these studies showed benefit to patients given tPA (and that, using analytical methods that they think flawed); four studies showed harm and had to be stopped before completion; and the remaining studies showed neither benefit nor harm. On the basis of this evidence, the NNT Group recommended against the use of tPA in acute ischaemic stroke. The NNT Group notes that the case for the 3-hour time window arises largely from analysis of two trials: NINDS-2 and subgroup results from IST-3. "However, presuming that early (0-3h) administration is better than later administration (3-4.5h or 4.5-6h) the subgroup results of IST-3 suggest an implausible biological effect in which early administration is beneficial, 3-4.5h administration is harmful, and 4.5-6h administration is again beneficial." Indeed, even the original publication of the IST-3 trial found that time-window effects were not significant predictors of outcome (p=0.61).
Sources: en.wikipedia.org
== Critical reception and reviews == Nikhil Krishnan of The Daily Telegraph rated The Half Known Life one out of five stars. Bilal Qureshi of The Washington Post wrote "“The Half Known Life” is a masterful merging of Iyer’s past and current concerns, a book of inner journeys told through extraordinary exteriors, of hopeful optimism for a world rooted in the paradise of being home.". The book has been reviewed by Mark Epstein of The New York Times, Tim Adams of The Guardian, Danny Heitman of The Wall Street Journal, Mini Kapoor of The Hindu, Caroline Eden of Financial Times, Thúy Đinh of National Public Radio and Paul Clement of The Irish Times.
The season premiered on the streaming service Amazon Prime Video on June 3, 2022, with its first three episodes. The remaining five episodes were released weekly until July 8, 2022. The season received critical acclaim with praise towards its action sequences, social commentary, visual effects, character development, story, and performances (particularly Urban, Quaid, Starr, McElligott, Alonso, and Ackles). This season is widely regarded as the best season of the show. It received multiple nominations including two Primetime Creative Arts Emmy Awards, earning one for stunt coordination. On June 10, 2022, the series was renewed for a fourth season.
Medea resolves to kill her own children as well, not because the children have done anything wrong, but because she feels it is the best way to hurt Jason. She calls for Jason once more and, in an elaborate ruse, apologizes to him for overreacting to his decision to marry Glauce. When Jason appears fully convinced that she regrets her actions, Medea begins to cry in mourning of the exile. She convinces Jason to allow their two sons to give gifts to Glauce in hopes that Creon will lift the exile against the children. Eventually Jason agrees.
== References == McGraw-Hill Encyclopedia of Science & Technology (10th ed.). New York: McGraw-Hill. 2007. ISBN 978-0-07-144143-8. Serway, Raymond A.; Moses, Clement J.; Moyer, Curt A. (1989), Modern Physics, Fort Worth: Harcourt Brace Jovanovich, ISBN 0-03-004844-3 Simmons, George F. (1972), Differential Equations with Applications and Historical Notes, New York: McGraw-Hill, LCCN 75173716
Sources: en.wikipedia.org
=== Reconstitution of the Indian Forest Service === Singh’s most significant administrative legacy was his successful advocacy for a unified national forestry cadre. He argued that the decentralized provincial structures were fragmented and vulnerable to local political pressures. Under his leadership, the Indian Forest Service was reconstituted and formalized under the All India Services Act, 1951. Notified on September 1, 1966, the IFS became the third All-India Service alongside the Indian Administrative Service (IAS) and the Indian Police Service (IPS). The reform established merit-based recruitment through the Union Public Service Commission (UPSC) and standardized training at the Forest Research Institute.
=== Aviation === In 2016, researchers developed a prototype de-icing system that incorporated unzipped carbon nanotube graphene nanoribbons in an epoxy/graphene composite. In laboratory tests, the leading edge of a helicopter rotor blade was coated with the composite, covered by a protective metal sleeve. Applying an electrical current heated the composite to over 200 °F (93 °C), melting a 1 cm (0.4 in)-thick ice layer with ambient temperatures of a -4 °F (-20 °C).
=== 2014 === The center delocalized the Production Site & Kiln Site to Tramniak to expand the activity center located on the Temples Road. The center offers a new activity that involves painting on pottery bisque.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.